Abstract
The development of the nervous system is critically dependent on the production of functionally diverse neuronal cell types at their correct locations. In the embryonic neural tube, dorsoventral signaling has emerged as a fundamental mechanism for generating neuronal diversity. In contrast, far less is known about how different neuronal cell types are organized along the rostrocaudal axis. In the developing mouse and chick neural tube, hindbrain serotonergic neurons and spinal glutamatergic V3 interneurons are produced from ventral p3 progenitors, which possess a common transcriptional identity but are confined to distinct anterior–posterior territories. In this study, we show that the expression of the transcription factor Neurogenin3 (Neurog3) in the spinal cord controls the correct specification of p3-derived neurons. Gain- and loss-of-function manipulations in the chick and mouse embryo show that Neurog3 switches ventral progenitors from a serotonergic to V3 differentiation program by repressing Ascl1 in spinal p3 progenitors through a mechanism dependent on Hes proteins. In this way, Neurog3 establishes the posterior boundary of the serotonergic system by actively suppressing serotonergic specification in the spinal cord. These results explain how equivalent p3 progenitors within the hindbrain and the spinal cord produce functionally distinct neuron cell types.
Introduction
The hindbrain and spinal cord both display a highly conserved pattern of dorsoventral gene expression. Fourteen cardinal populations of neurons have been identified in the spinal cord on the basis of their transcription factor profiles, axonal projections, and neurotransmitter phenotypes (Jessell, 2000; Briscoe and Novitch, 2008; Goulding, 2009). Thirteen of these populations are conserved in the hindbrain (Gray, 2008). Neurons derived from the most ventral progenitor domain, termed p3, are an exception to this rule with serotonergic (5-HT) neurons generated in the hindbrain and glutamatergic V3 interneurons in the spinal cord (Briscoe et al., 1999; Zhang et al., 2008; Jacob et al., 2013).
During embryonic development, serotonergic neurons emerge from hindbrain p3 progenitors that express the transcription factors Nkx2.2, Foxa2, and Ascl1 (Briscoe et al., 1999; Pattyn et al., 2004; Jacob et al., 2007). 5-HT neuron differentiation requires the orchestrated action of Gata2, Lmx1b, and Pet1 (Hendricks et al., 1999, 2003; Cheng et al., 2003; Ding et al., 2003; Craven et al., 2004). In the spinal cord, the establishment of p3 identity also requires Nkx2.2, Foxa2, and Ascl1 (Briscoe et al., 1999; Dessaud et al., 2007; Jacob et al., 2013; this study). However, instead of producing serotonergic neurons, they produce glutamatergic V3 interneurons that selectively express the transcription factor Sim1 (Briscoe et al., 1999; Zhang et al., 2008). Excitatory V3 neurons are components of intraspinal networks that generate organized motor patterns (Zhang et al., 2008; Borowska et al., 2013). In contrast, serotonergic neurons innervate large regions of the brain and the spinal cord, where they modulate a variety of behaviors from anxiety and aggression to breathing and locomotion (Müller and Jacobs, 2010; Deneris and Wyler, 2012).
The exact mechanism that ensures the production of regionally restricted serotonergic and V3 fates is still poorly understood. Recently, Jacob et al. (2013) have shown that reduced expression of the transcription factor Ascl1 in the spinal cord favors V3 differentiation to the detriment of serotonergic development. However, the intrinsic mechanisms that repress Ascl1 and exclude 5-HT differentiation from the spinal cord remain to be determined. Interestingly, lamprey, fish, and amphibians contain serotonergic neurons in their ventral spinal cord (Harris-Warrick et al., 1985; Branchereau et al., 2000; Lillesaar, 2011), suggesting that the mechanism that prevents p3 progenitors from differentiating as serotonergic neurons may be specific to the embryonic spinal cord of amniotes.
In this study, we show that the transcription factor Neurog3, which is expressed in the mouse ventral spinal cord (Sommer et al., 1996; Lee et al., 2003) but not in zebrafish spinal cord (Wang et al., 2001), controls the correct specification of p3-derived neurons by suppressing serotonergic neuron production. We provide strong genetic evidence that Neurog3 ensures the assignment of V3 identity by reducing Ascl1 expression through a mechanism that involves the transcriptional repressor Hes5. In the absence of Neurog3, spinal p3 progenitors fail to adopt a complete caudal character, which results in heterotopic development of serotonergic neurons at the expense of V3 interneurons.
Materials and Methods
Animals.
All experiments involving animals were conducted according to the protocols approved by the Institutional Animal Care and Use Committee of the Fundación Instituto Leloir. Genotyping of Neurog3 (Gradwohl et al., 2000), Ascl1 (Guillemot et al., 1993), Nkx2.2 (Briscoe et al., 1999), Ascl1CreER (Kim et al., 2011), Sim1Cre (Zhang et al., 2008), UncxlacZ (Mansouri et al., 2000), CAG:CreER (Hayashi and McMahon, 2002), Ascl1flox (Pacary et al., 2011), Gata2GFP (Suzuki et al., 2006), and Ai14 tdTomato conditional reporter (Madisen et al., 2010) mice were performed by PCR using allele-specific primers for each strain.
Time pregnancies were determined by detection of vaginal plug and midday was designated E0.5. Induction of Cre activity in Ascl1CreER mice was achieved by tamoxifen administration (TAM; 150 mg/kg b.w., i.p.) to pregnant females at the indicated stages.
Embryos were dissected in PBS buffer. After decapitation, embryos were pinned on Sylgard plates, eviscerated, and fixed for 1 h in 4% PFA in PBS. They were cryoprotected in 20% sucrose (overnight, 4°C) before embedding in Cryoplast (Biopack). Stage-matched littermates of desired genotypes were aligned and embedded together to ensure identical processing conditions. Tissue was cryosectioned 30 μm thick (Leica 3050S; Leica Biosystems).
In situ hybridization and immunohistochemistry.
Nonradioactive in situ hybridization was performed essentially as previously described (Lanuza et al., 2004). Briefly, sections were dried at 55°C for 20 min, fixed 15 min with PFA 4% in PBS, and washed three times with PBS-DEPC. Tissue was treated 3 min with proteinase K (3 μg/ml), followed by PFA 4% 10 min and three PBS washes. Slides were incubated in triethanolamine-acetic anhydrate pH 8.0 for 10 min, permeabilized with Triton X-100 1% in PBS for 30 min, and washed with PBS. Sections were incubated for 2 h with hybridization solution (50% formamide, 5× SSC, 5× Denhardt solution, and 250 μg/ml yeast tRNA). DIG-labeled RNA probes were generated by in vitro transcription using T7, T3, or sp6 RNA polymerases (Promega), DIG-UTP (Roche), rNTPs (Promega), and PCR-amplified products or linearized plasmids as templates. RNA probes used were mNeurog3 (this study), mSim1 (Zhang et al., 2008), mUncx (Mansouri et al., 2000), mAscl1 (Kriks et al., 2005), mNkx2.2 (Briscoe et al., 1999), mGata2 (this study), mLmx1b (Cheng et al., 2003), ratPet1 (Fev; Hendricks et al., 1999), mvGluT2 (Slc17a6; Lanuza et al., 2004), mSerT (Slc6a4; this study), mvGluT3 (Slc17a8; Cheng et al., 2003), mHes5 (Hojo et al., 2000), mvAChT (Slc18a3; Zhang et al., 2008), chickSim1 (this study), chickAscl1 (Tsarovina et al., 2004), chickNeurog3 (this study), and chickHes5-1 and 5-2 (Fior and Henrique, 2005).
DIG-labeled probes were diluted in hybridization solution, denatured at 80°C for 5 min, and added on the slides. Incubation was performed for 14 h at 68°C. Sections were washed three times, 45 min, at 68°C with 1× SSC, 50% formamide. For immunodetection of DIG, slides were blocked with 10% HI-serum in PBS containing 0.1% Tween 20 for 1–2 h (room temperature, RT) and incubated overnight at 4°C with alkaline phosphatase-labeled sheep anti-DIG antibody (Roche) diluted in blocking solution. After washing 3× 10 min, enzymatic activity was detected by using BCIP (0.15 mg/ml; Roche) and NBT (0.18 mg/ml; Roche) in reaction solution (Tris, pH 9.5, 0.1 m, MgCl2 50 mm, NaCl 0.1 m, and Tween 20 0.1%). Bright-field pictures were captured by digital camera on Zeiss Axioplan microscope.
Antibody stainings were performed essentially as previously described (Lanuza et al., 2004). Briefly, cryostat sections were washed three times in PBS containing 0.1% Triton X-100 (PBST) and treated with blocking solution (5% HI-serum in PBST) for 1 h. Primary antibodies at the appropriate dilutions in blocking solution were incubated overnight at 4°C. The following antibodies were used: mouse anti-Neurog3, mouse anti-Nkx2.2, mouse anti-Nkx6.1, mouse anti-Isl1/2 (Developmental Studies Hybridoma Bank, DHSB), mouse anti-Ascl1 (BD Biosciences), rabbit anti-Nkx2.2 (Tom Jessell, Columbia University, NY), goat anti-Sox2 (Santa Cruz Biotechnology), mouse anti-βIII-tubulin (Sigma), rabbit anti-Olig2 (Millipore Bioscience Research Reagents), mouse anti-Foxa2 (Abcam), chicken anti-β-gal (Abcam), rabbit anti-GFP (Invitrogen), chicken anti-GFP (Aves Laboratories), rabbit anti-dsRed (Clontech), rabbit anti-5HT (ImmunoStar), mouse anti-Cre (Sigma), and rabbit anti-Lhx3 (Sam Pfaff, The Salk Institute, La Jolla, CA).
After incubation, slides were washed 3× 10 min each with PBST and incubated with Cy-labeled, species-specific secondary antibodies (Jackson ImmunoResearch) for 2–3 h at RT. Sections were dehydrated in ethanol/xylene series and mounted using DPX (Sigma-Aldrich). Images were captured using Zeiss LSM5 Pascal and Zeiss LSM 510 Meta confocal microscopes and assembled using Adobe Photoshop and Adobe Illustrator.
In ovo electroporation.
Full-length cDNA of mNeurog3 and cHes5-1 (provided by Domingos Henrique; Fior and Henrique, 2005) were cloned into pCAG-IRES-EGFP vector. Dominant-negative retinoic acid receptor hRAR403 expression plasmid (provided by Shan Sockanathan) and CAG-rAscl1-ires-GFP construct were previously used (Sockanathan et al., 2003; Kriks et al., 2005). Chick electroporation was performed essentially as described previously (Muramatsu et al., 1997).
Quantitations and statistical analysis.
At least six sections were examined from each embryo, and no less than three embryos of each genotype were used. Thoracic and upper lumbar spinal cord segments and r6–r7 rhombomeres were analyzed.
Integration of in situ hybridization signals was performed using a MATLAB (The MathWorks) script on nonprocessed images. Background levels were defined by the mean intensity along the perimeter of the selected area and positive pixels were defined as those above background mean + 2 standard deviations (SD).
Ascl1 expression levels were assessed using a MATLAB script that measured the mean intensity of individual nuclei. Ascl1 intensity of cells located within the p3/Nkx2.2+ domain was corrected by subtracting background levels. For each section, background intensity was determined as the mean intensity of 10 progenitor cells located in the motoneuron progenitor domain (pMN), which do not express Ascl1. A cell was considered “HIGH” when its intensity was above the mean + 1 SD of wild-type spinal p3 Ascl1 intensity.
Differences between groups were evaluated by nonparametric Mann–Whitney test or Kruskal–Wallis ANOVA with post hoc Dunn's multiple-comparison test (GraphPad Software). Results were considered statistically significant when p < 0.05. Data are presented as mean ± SD.
Results
Neurogenin3 is expressed in the spinal cord p3 domain
Ventral p3 progenitors of the mouse hindbrain and spinal cord produce 5-HT neurons and V3 interneurons, respectively (Fig. 1A–I). In the developing ventral hindbrain, the expression of the transcription factors Gata2, Lmx1b, and Pet1 delineate the differentiation of serotonergic neurons (Fig. 1A–D,G), whereas in the spinal cord, Nkx2.2 progenitors produce glutamatergic V3 neurons that are identified by the transcription factors Sim1 and Uncx (Fig. 1A,E,F,H). In searching for intrinsic controllers of these divergent neuronal fates, we first explored the spatial and temporal pattern of expression of the bHLH transcription factor Neurog3. In E10.5 embryos, Neurog3 expression was found largely restricted to the most ventral domain of the spinal cord (Fig. 1K). Immunohistochemical analysis with antibodies against Neurog3 and Nkx2.2 showed that all Neurog3-expressing cells in the developing spinal cord are Nkx2.2 positive (Fig. 1M,N). Neurog3 is not homogenously expressed in all Nkx2.2+ cells, with Neurog3+ cells occupying lateral positions within the spinal p3 ventricular zone (Fig. 2E–J). This suggests that Neurog3 is either oscillatory or preferentially expressed in committed precursors, similar to the expression patterns seen for other bHLH proteins (Bertrand et al., 2002; Imayoshi and Kageyama, 2014). In contrast to the robust expression of Neurog3 in the p3 domain of the embryonic spinal cord, topographically related p3 progenitors of the hindbrain are negative for Neurog3 (Fig. 1J–N).
In the spinal cord, Neurog3-expressing cells are embedded in Nkx6.1 domains (Fig. 2A), positioned ventral to motoneuron progenitors that are marked by the expression of Olig2 and Lhx3 (Fig. 2B,C), and excluded from the floor plate (Foxa2HIGH; Fig. 2D). Neurog3 expression in the ventral spinal cord is limited to the ventricular zone, as indicated by colabeling with the progenitor cell marker Sox2 (Fig. 2E) and its exclusion from βIII-tubulin+ newborn neurons (Fig. 2F). Furthermore, Neurog3 in the p3 domain of the spinal cord precedes the appearance of the transcription factors Sim1 and Uncx, which are both induced in newly generated neurons as they leave the ventricular zone and acquire postmitotic V3 neuronal identity (Fig. 2G–J). The absence of double labeling of Neurog3 and Cre in the Sim1Cre neural tube, and Neurog3 and β-galactosidase in UncxlacZ knockin mice, argues that Neurog3 is rapidly downregulated during V3 neurogenesis.
The limited expression of Neurog3 to the ventrocaudal neural tube suggests that it lays downstream of signals acting along the orthogonal axes of the developing nervous system. In view of the preeminent role that retinoid signaling plays in the anterior–posterior patterning of the neural tube and serotonergic neuron development (Muhr et al., 1999; Liu et al., 2001; Maden, 2006; Jacob et al., 2013), we asked if retinoid signaling contributes to restrict Neurog3 to the spinal cord. In keeping with previous experiments showing an anterior-low, posterior-high gradient of retinoic acid in the hindbrain–spinal cord (Maden, 2006; Jacob et al., 2013), electroporation of a dominant-negative version of the retinoic acid receptor (RAR403; Sockanathan et al., 2003) in the chick spinal cord markedly decreased Neurog3 levels (Fig. 2K), suggesting that Neurog3 is under the control of retinoid signaling. On the other hand, the selective expression of Neurog3 to the most ventral domain of the spinal cord depends on the transcription factor Nkx2.2, which is induced by sustained Shh signaling (Briscoe et al., 1999; Dessaud et al., 2007). The spinal cord of Nkx2.2 mutants lacks ventral cells that express high levels of Neurog3 (Fig. 2L,M). Conversely, the expansion of the p3/Nkx2.2+ domain in Pax6 mutant embryos (Ericson et al., 1997; Briscoe et al., 1999) resulted in an increased number of Neurog3+ cells that spread dorsally (Fig. 2L,M).
Interplay between Neurog3 and Ascl1 establishes the caudal boundary for serotonergic specification
Recent studies indicate that the expression level of the bHLH transcription factor Ascl1 strongly influences the choice between serotonergic and V3 cell fates with Ascl1 highly expressed in the hindbrain (Pattyn et al., 2004; Jacob et al., 2013). This suggests that the suppression of Ascl1 expression in caudal neural tube is a key step in establishing the glutamatergic V3 cell differentiation program. We first compared the expression of Neurog3 and Ascl1 in the p3 domain of the spinal cord throughout development. Neurog3 is initially absent from this domain at E9.5, and begins to be expressed at approximately E10 (Fig. 3A,D). Ascl1, on the other hand, displays an inverse temporal pattern. It is robustly expressed in Nkx2.2+ spinal cells at E9.5, but is sharply downregulated at later stages (Fig. 3B,E). The dynamic pattern of Ascl1 in the developing spinal cord was also analyzed in Ascl1CreER;CAG:floxstop-tdTomato mice. By retrospectively evaluating Ascl1 expression at E11.5, we detected p3-derived tdTomato+ cells when tamoxifen was administered at E9.5 (Fig. 3G, arrowhead), but not when induced at E10.5 (Fig. 3G). This downregulation of Ascl1 in the spinal cord p3 domain contrasts with Ascl1 expression in the hindbrain (Pattyn et al., 2004), where it remains elevated from E9.5 to E11.5 (Fig. 3C). Measurement of Ascl1 intensity in individual p3 cells of the hindbrain and spinal cord at E11.5 reflected quantitative differences in Ascl1 levels (Fig. 3F) as previously shown (Jacob et al., 2013).
We then mapped Neurog3 and Ascl1 expression along the rostrocaudal axis of the E11.5 neural tube. As shown above (Fig. 1J–N), Neurog3 expression was restricted to the spinal cord p3 domain and excluded from the hindbrain (Fig. 3I). On the contrary, Ascl1 was robustly expressed in hindbrain p3 progenitors, and only at low to undetectable levels in spinal p3 ventricular cells (Fig. 3I,F; Jacob et al., 2013). In the hindbrain–spinal cord transition, we observed a sharp inversion in the numbers of Neurog3+ and Ascl1HIGH cells (Fig. 3I–K, pink area), with the Ascl1- and Neurog3-expressing territories strictly corresponding to those that give rise to serotonergic and V3 interneurons, respectively (Fig. 3H).
We then investigated whether this differential anterior–posterior Ascl1 expression correlates with specific and different roles in neuronal specification. Consistent with previous reports that showed that serotonergic differentiation requires Ascl1 (Pattyn et al., 2004), we found that ventral hindbrain of Ascl1 mutants lack expression of the transcription factors Gata2 and Pet1 (Fig. 3L,M). In contrast, we found that Sim1 and Uncx were largely unaffected in Ascl1−/− spinal cord (Fig. 3N,O), demonstrating that Ascl1 in the ventral spinal cord is dispensable for V3 interneuron specification.
Together, our results show that early p3 progenitors initially express high levels of Ascl1 along the entire length of the neural tube, and that the upregulation of Neurog3 in spinal p3 cells coincides with Ascl1 downregulation. In the hindbrain, the absence of Neurog3 correlates with Ascl1 maintenance, and the consequent serotonergic differentiation.
Neurog3 represses Ascl1 expression and switches from serotonergic to glutamatergic neurogenesis
To better understand how the complementary Neurog3 and Ascl1 expression patterns are established, we performed gain-of-function experiments by in ovo electroporation in the chick embryo, where the dynamics of Neurog3 expression is similar to the mouse (Fig. 4A–C). First, Neurog3 was misexpressed early during spinal cord development, preceding the endogenous induction of Neurog3 (Fig. 4B). Electroporation of a Neurog3-IRES-GFP plasmid into E2 chick neural tube reduced ventral spinal cord Ascl1 levels, compared with the contralateral unelectroporated side (Fig. 4D) or to the electroporation of a control GFP vector (not shown). Furthermore, forced expression of Neurog3 in the ventral hindbrain, where Neurog3 is absent (Fig. 4A), consistently suppressed Ascl1 expression (Fig. 4E,F), without affecting the dorsoventral extension of the p3 domain as assessed by Nkx2.2 immunostaining (Fig. 4E, inset).
As development proceeds, repression of Ascl1 elicited by Neurog3 electroporation in the hindbrain was followed by a marked reduction in the number of serotonergic neurons (Fig. 4F). In these embryos, the decrease in 5-HT+ cells was accompanied by the ectopic production of V3-Sim1+ neurons in the hindbrain (Fig. 4F). To assess if the reduced serotonergic differentiation induced by Neurog3 required Ascl1 repression, we coelectroporated Neurog3 and Ascl1, and found that serotonergic neurogenesis was restored (Fig. 4G). These results show that ectopic overexpression of Neurog3 in the ventral hindbrain forces the acquisition of a spinal p3 identity in which reduced Ascl1 levels anticipate the suppression of serotonergic specification. Furthermore, the heterochronic expression of Neurog3 in the spinal cord (Fig. 4D) suggests that the role of Neurog3 is to reduce Ascl1 expression levels in spinal p3 progenitors, which allows the subsequent differentiation of glutamatergic V3 neurons.
Hes5 mediates Neurog3-dependent Ascl1 repression
To gain further insights into the mechanism underlying Ascl1 repression by Neurog3 in p3 spinal progenitors, we analyzed Hes proteins, which are transcriptional repressors of Ascl1 that usually act downstream of Notch signaling (Bertrand et al., 2002; Kageyama et al., 2007). The complementary Ascl1 and Hes5 patterns along the p3 domain (Jacob et al., 2013) resemble the reciprocal expression of Ascl1 and Neurog3 (Fig. 3I). This correlation suggests that the modulation of Ascl1 by Neurog3 in spinal p3 progenitors could functionally involve Hes5.
The electroporation of Hes5 in the developing chick hindbrain was seen to downregulate Ascl1 in the p3 domain and to suppress 5-HT neuron specification (Fig. 4H). To test whether Neurog3 could regulate Ascl1 via Hes5, we electroporated Neurog3 in the chick hindbrain and assessed Hes5 expression. Misexpression of Neurog3 induced Hes5-1 and Hes5-2 expression in the transfected hindbrain p3 domain (Fig. 4I, arrowhead), in contrast to the nonelectroporated side where there is a gap in Hes expression (Fig. 4I, arrow). Interestingly, the induction of Hes5 by Neurog3 was not restricted to the hindbrain, since Hes5 upregulation was also evident when Neurog3 was targeted into the spinal cord (data not shown). Consistent with the finding that Neurog3 is able to induce Hes5, Neurog3 mutant embryos show significantly reduced Hes5 levels in the spinal p3 domain (Fig. 4J, arrowhead, K), while its expression in more dorsal ventricular progenitors remained normal (Fig. 4J, arrow). These results provide strong evidence that Hes5 repressor proteins function downstream of Neurog3 to elicit Ascl1 downregulation in p3 spinal progenitors. We propose that this step is necessary to produce the full complement of glutamatergic V3 neurons (see below).
Ascl1 is maintained at high levels in spinal p3 precursors in Neurog3 mutants
To address whether Neurog3 plays a physiological role in regulating Ascl1 expression in the ventral spinal cord and, in turn, neuron identity, we analyzed the Neurog3 mutant ventral spinal cord and found a marked increase in the number of cells expressing high levels of Ascl1 (Fig. 5A,B). Quantitative analysis in individual spinal cells revealed that Ascl1 levels in Neurog3−/− p3 cells are significantly higher than in their wild-type littermates (Fig. 5C) and similar to Ascl1 levels in the p3 hindbrain (Fig. 3F). This result demonstrates that Neurog3 expression in the spinal cord, which starts around E10 (Fig. 3A,D), is essential to achieve the low levels of Ascl1 that are a defining feature of spinal p3 progenitors. Interestingly, the loss of Neurog3 does not affect the number of Nkx2.2+ cells in the neural tube (Fig. 5D,E) nor the position of the p3-pMN boundary (Fig. 5F,G). Moreover, the motoneuron population in the Neurog3−/− spinal cord is not altered (Fig. 5H–J), and the expression of Foxa2 in p3 cells is retained at low levels, similar to wild types (Fig. 5K,L). Thus, Neurog3 is not required for dorsoventral identity, but is necessary to limit the expression of Ascl1 in spinal p3 cells, which otherwise would acquire a rostral hindbrain character.
The mutual exclusion between Neurog3 and Ascl1 prompted us to test whether Neurog3 and Ascl1 function in a cross-repressive fashion. However, we found that the repressive interaction between Neurog3 and Ascl1 is asymmetrical. Neither Ascl1 mutants, nor conditional mutant embryos in which Ascl1 was acutely deleted by tamoxifen (CAG:CreER;Ascl1flox/flox), showed Neurog3 expression in the ventral hindbrain (Fig. 6A–D). In addition, in the Ascl1 mutant spinal cord Neurog3 expression still starts around E10, similar to wild-type embryos (Fig. 6E–H). These experiments rule out a scheme of reciprocal inhibition between Neurog3 and Ascl1, but support a model in which Neurog3 represses Ascl1 in the developing spinal cord.
Neurog3 suppresses 5-HT fate in the spinal cord
Serotonergic raphe neurons are produced exclusively from ventral hindbrain p3 progenitors that express the transcription factors Nkx2.2 and Foxa2, which together with Ascl1 are required for their specification (Briscoe et al., 1999; Pattyn et al., 2004; Jacob et al., 2007, 2013). To address whether the persistent Ascl1 expression in the spinal cord of Neurog3 mutants is indicative of the acquisition of rostral/hindbrain identity, we asked whether spinal progenitors that normally give rise to glutamatergic V3 neurons are redirected into a serotonergic differentiation program.
We found that high levels of Ascl1 in Neurog3−/− spinal p3 cells (Figs. 5A–C, 7A) are closely associated with the ectopic expression of Gata2, Lmx1b, and Pet1 (Fig. 7B–D), which are key transcription factors of the postmitotic genetic program driving serotonergic fate (Hendricks et al., 1999, Hendricks et al., 2003; Cheng et al., 2003; Ding et al., 2003; Craven et al., 2004) and are never expressed in Nkx2.2-derived cells of the spinal cord (Fig. 1B–D).
The generation of ectopic spinal serotonergic neurons in Neurog3 mutants was in all cases entirely restricted to the ventral neuroepithelium. To determine whether ectopic serotonergic neurons in Neurog3-null spinal cords require Nkx2.2, as do 5-HT-neurons in the hindbrain (Briscoe et al., 1999; Cheng et al., 2003; Pattyn et al., 2003), we generated Nkx2.2/Neurog3 and Pax6/Neurog3 double mutants. Nkx2.2/Neurog3 double knock-outs did not show signs of ectopic 5-HT neuron differentiation in their spinal cord (Fig. 7E–H). This contrasts starkly with Pax6/Neurog3 double mutants that have an extended Nkx2.2+ domain (Fig. 2L) and display a ∼2-fold increase in the expression of Ascl1, Gata2, Lmx1b, and Pet1 compared with the simple Neurog3 knock-out (Fig. 7E–H).Together, these results confirm that ectopic spinal serotonergic neurons originate from Nkx2.2+ cells in the absence of Neurog3. These experiments also demonstrate that spinal p3 cells are bipotential progenitors, which when lacking Neurog3 adopt the transcriptional program that specifies serotonergic neurons in the ventral hindbrain (Deneris and Wyler, 2012).
To further characterize the heterotopic serotonergic neurons in the spinal cord of Neurog3 mutants, we assessed the presence of 5-HT and found immunoreactive neurons in the ventral spinal cord of Neurog3−/− E12.5 embryos and P0 pups (Fig. 7I,J). 5-HT+ intraspinal processes were also identified in the ventrolateral funiculus at E12.5 (Fig. 7I, arrows), when hindbrain serotonergic projections have not reached the thoracic and upper lumbar segments analyzed. In addition, inspection of Neurog3−/− P0 animals showed that ectopic 5-HT+ neurons locate in the ventromedial and ventrolateral spinal cord and project locally through the ventral funiculus (Fig. 7K–M). Moreover, Neurog3−/− spinal cords display ectopic induction of the serotonin transporter SerT (Fig. 7N), together with the vesicular glutamate transporter vGluT3 (Fig. 7O), which is a specific marker of 5-HT neurons (Cheng et al., 2003).
Finally, we found that the ectopic generation of serotonergic neurons in the spinal cord of Neurog3 mutants is produced at the expense of glutamatergic V3 interneurons. The analysis of the V3 identity markers Sim1 and Uncx showed that the spinal cord of Neurog3−/− displays a ∼50% reduction in these transcription factors (Fig. 8A,B,D,E; Lee et al., 2003). In addition, the decreased number of glutamatergic V3 neurons in the spinal cord of Neurog3 mutants is made evident by a significantly lower expression of the vesicular glutamate transporter vGluT2 (Fig. 8C,F). In the absence of Neurog3, spinal p3 progenitors produce both V3/Sim1+ cells and Gata2+/Pet1+ serotonergic neurons (Fig. 8G), and later each neuronal population follows distinctive migratory pathways, as shown at E12.5 (Fig. 8H). It is noteworthy that the position of newly generated ectopic 5-HT neurons at E11.5, proximal to the ventricular zone, may reflect that they are preferentially produced in a delayed neurogenic wave, similar to their development in the hindbrain (Pattyn et al., 2003; Jacob et al., 2007).
Discussion
In this study, we show that the transcription factor Neurog3 controls cell identity in the p3 domain of the spinal cord where it suppresses serotonergic specification. The restricted expression of Neurog3 in ventral spinal p3 cells results from the composite activities of ventralizing and caudalizing signals. Neurog3 depends both on Nkx2.2, in response to high and prolonged Shh signaling (Briscoe et al., 1999; Dessaud et al., 2007), and on retinoids, which encode a caudalizing activity (Muhr et al., 1999; Liu et al., 2001; Maden, 2006). Similar to other bHLH transcription factors (Bertrand et al., 2002; Imayoshi and Kageyama, 2014), Neurog3 appears to be robustly expressed in committed p3 precursors but sharply downregulated when converted into postmitotic V3 neurons.
Both gain- and loss-of-function experiments in the chick and mouse embryo demonstrate that Neurog3 regulates neuronal fate choice in the p3 progenitor domain by translating regional signals along the anterior–posterior axis into differential Ascl1 expression (Jacob et al., 2013). Thus, by reducing Ascl1 levels in spinal p3 progenitors, Neurog3 excludes serotonergic differentiation and allows V3 neurogenesis in the spinal cord (Fig. 8I). We propose that the efficient downregulation of Ascl1 and cell fate control by Neurog3 is, at least partially, a non-cell-autonomous process (see Fig. 8I). This mechanism is supported by the observations that Neurog3 is not homogenously expressed in all p3 cells, and that Hes5, a classical target of Notch signaling, is responsible for Ascl1 transcriptional repression in the p3 domain.
Our results show that in the absence of Neurog3, spinal p3 cells produce serotonergic neurons. However, some V3 interneurons do differentiate in the Neurog3−/− spinal cord. This incomplete conversion can be explained by Ascl1 not being equally de-repressed in all spinal p3 cells (Fig. 5). It is possible that other caudalizing signals (Jacob et al., 2013), still present in Neurog3 mutants, normally operate together with Neurog3 to achieve low Ascl1 expression and secure the exclusion of 5-HT neurons from the spinal cord (Fig. 8I). Nevertheless it remains possible that the incomplete neuronal fate change reflects the existence of p3 cell subpopulations or temporally coordinated neurogenic waves whose specification programs are differentially affected by the loss of Neurog3.
The results presented favor the notion that Neurog3 function is to suppress Ascl1 expression and 5-HT neurogenesis in the spinal cord, rather than instructing V3 differentiation. Actually, Neurog3 is not strictly required for V3 interneuron specification, as some V3 interneurons are still generated in Neurog3−/− spinal cords (Fig. 8A–F). The reduction observed in V3 numbers in Neurog3 mutants can be attributed to spinal p3 progenitors acquiring a serotonergic fate (Fig. 5, 7). Nevertheless, we cannot rule out that Neurog3 may be additionally required to acquire a complete V3 character including neurotransmitter identity, since vGluT2 expression is more strongly affected by Neurog3 loss compared with Sim1 and Uncx (Fig. 8A–F).
In other systems, Neurog3 is a known genetic switch that balances between alternative cell fates from pluripotent progenitors. In the pancreas Neurog3 specifies endocrine against exocrine fates from multipotent pancreatic progenitors (Gradwohl et al., 2000). In the hypothalamus, Neurog3 selects POMC at the expense of NPY and TH neurons (Pelling et al., 2011). In contrast to these roles, our experiments suggest a novel function for Neurog3, in which it provides distinct regional identities to spinal cord and hindbrain p3 progenitors. In this context, Neurog3, together with differential retinoid activity (Jacob et al., 2013), serves as a mechanism for interpreting anterior–posterior positioning to impose the caudal border for the serotonergic system in amniotes.
In the mammalian central nervous system serotonergic neurons are found exclusively in the raphe nuclei. In contrast, aquatic vertebrates, including the lamprey, fish, and amphibians, contain both the brainstem raphe system and 5-HT cells embedded in the spinal cord motor networks (Harris-Warrick et al., 1985; Branchereau et al., 2000; Lillesaar, 2011). In the vertebrate spinal cord, 5-HT plays an important role in organizing the locomotor pattern and can profoundly modulate the motor output (Schmidt and Jordan, 2000). However, the functional significance of local intraspinal serotonergic neurons is unclear, but might be related to phylogenetic locomotor modalities. In species lacking an intrinsic serotonergic spinal system, such as mammals, these functions may have been lost or may have been co-opted by raphe 5-HT descending projections. We hypothesize that the expression of Neurog3 in the embryonic spinal cord is important in this evolutionary change. Supporting this proposal, studies in zebrafish have shown that Neurog3 is not expressed in the developing spinal cord (Wang et al., 2001). The absence of Neurog3 correlates with the production of Pet1-expressing 5-HT+ neurons in the ventromedial spinal cord of zebrafish larvae (McLean and Fetcho, 2004; Lillesaar et al., 2009).
In summary, our study demonstrates that spinal p3 progenitors have the potential to produce serotonergic and V3 interneurons, with the expression of Neurog3 being sufficient to suppress the transcriptional program that supports 5-HT neuron development. Neurog3 restricts serotonergic development to the hindbrain and allows the production of a complete cohort of glutamatergic V3 interneurons necessary to establish robust and balanced spinal locomotor rhythms (Zhang et al., 2008; Borowska et al., 2013).
Footnotes
This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica grants (PICT-2011-1350 and PICT-2009-PRH-72) and the International Brain Research Organization Return Home Award to G.M.L., G.M.L. is an established investigator of the Consejo Nacional de Investigaciones Científicas y Técnicas. We thank Maximiliano Neme for MATLAB script edition and Alejandro Schinder, Greg Lemke, and Micaela Sartoretti for critical comments on this manuscript. We also acknowledge Susana Godoy (Granja Tres Arroyos) for fertilized eggs; Quifu Ma, Domingos Henrique, Shan Sockanathan, Ryoichiro Kageyama, Hermann Rohrer, Tom Jessell, and Lidia Szczupak for plasmids or antibodies; John Rubenstein for Nkx.2.2 mice; Ahmed Mansouri for UncxLacZ mice; Jane Johnson for Ascl1CreER; and Doug Engel for the Gata2GFP line.
The authors declare no competing financial interests.
- Correspondence should be addressed to Guillermo M. Lanuza, Developmental Neurobiology Lab, Instituto Leloir and Consejo Nacional de Investigaciones Científicas y Técnicas (IIBBA-CONICET), Buenos Aires 1405, Argentina. GLanuza{at}Leloir.org.ar